In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

Recently, several β-lactam (BL)/β-lactamase inhibitor (BLI) combinations have entered clinical testing or have been marketed for use, but limited direct comparative studies of their in vitro activity exist. Xeruborbactam (XER, also known as QPX7728), which is undergoing clinical development, is a cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lomovskaya, Olga, Castanheira, Mariana, Lindley, Jill, Rubio-Aparicio, Debora, Nelson, Kirk, Tsivkovski, Ruslan, Sun, Dongxu, Totrov, Maxim, Loutit, Jeffery, Dudley, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Mechanisms of Resistance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648875/
https://www.ncbi.nlm.nih.gov/pubmed/37800963
http://dx.doi.org/10.1128/aac.00440-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648875/
https://www.ncbi.nlm.nih.gov/pubmed/37800963
http://dx.doi.org/10.1128/aac.00440-23

Ejemplares similares